Advanced search
Publication Cover
Journal of Dermatological Treatment Volume 33, 2022 - Issue 5
Submit an article Journal homepage
2,484
Views
2
CrossRef citations to date
0
Altmetric
Short Reports

Serum drug levels and anti-drug antibodies in the context of dose tapering by interval prolongation of adalimumab, etanercept and ustekinumab in psoriasis patients: results of the CONDOR trial

Selma Atalaya Department of Dermatology, Radboudumc, Nijmegen René Descartesdreef 1, Nijmegen, NetherlandsORCID Iconhttps://orcid.org/0000-0002-9671-0386View further author information
ORCID Icon,
Sophie E. Berendsb Department of Hospital Pharmacy, Academic Medical Center, Amsterdam, NetherlandsORCID Iconhttps://orcid.org/0000-0002-3236-0698View further author information
ORCID Icon,
Hans M. M. Groenewoudc Department for Health Evidence, Radboud Institute for Health Sciences, Radboudumc, Nijmegen, NetherlandsORCID Iconhttps://orcid.org/0000-0002-4974-150XView further author information
ORCID Icon,
Ron A. A. Mathotb Department of Hospital Pharmacy, Academic Medical Center, Amsterdam, NetherlandsORCID Iconhttps://orcid.org/0000-0001-8401-0879View further author information
ORCID Icon,
David M. Njood Department of Dermatology, Ziekenhuis Groep Twente, Hengelo, NetherlandsORCID Iconhttps://orcid.org/0000-0003-1424-5722View further author information
ORCID Icon,
Johannes M. Mommerse Department of Dermatology, Sint Anna Ziekenhuis, Geldrop, NetherlandsORCID Iconhttps://orcid.org/0000-0002-4930-4107View further author information
ORCID Icon,
Paul M. Ossenkoppelef Department of Dermatology, Ziekenhuis Groep Twente, Almelo, NetherlandsORCID Iconhttps://orcid.org/0000-0002-7311-7213View further author information
ORCID Icon,
Marjolein I. A. Koetsierg Department of Dermatology, Gelre Ziekenhuizen, Apeldoorn, NetherlandsORCID Iconhttps://orcid.org/0000-0002-7823-8380View further author information
ORCID Icon,
Maartje A. Berendsh Department of Dermatology, Slingelandziekenhuis, Doetinchem, NetherlandsORCID Iconhttps://orcid.org/0000-0003-3851-1407View further author information
ORCID Icon,
Annick de Vriesi Biologics Lab, Bioanalysis, Sanquin Diagnostic Services, Amsterdam, NetherlandsORCID Iconhttps://orcid.org/0000-0001-7570-473XView further author information
ORCID Icon,
Peter C. M. van de Kerkhofa Department of Dermatology, Radboudumc, Nijmegen René Descartesdreef 1, Nijmegen, NetherlandsORCID Iconhttps://orcid.org/0000-0003-0084-3131View further author information
ORCID Icon,
Alfons A. den Broederj Department of Rheumatology, Sint Maartenskliniek, Nijmegen, NetherlandsORCID Iconhttps://orcid.org/0000-0002-9012-4079View further author information
ORCID Icon,
Elke M. G. J. de Jonga Department of Dermatology, Radboudumc, Nijmegen René Descartesdreef 1, Nijmegen, Netherlands;k Radboud University, Nijmegen, NetherlandsORCID Iconhttps://orcid.org/0000-0003-3872-5704View further author information
ORCID Icon &
Juul M. P. A. van den Reeka Department of Dermatology, Radboudumc, Nijmegen René Descartesdreef 1, Nijmegen, NetherlandsCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-3642-2673View further author information
ORCID Icon show all
Pages 2680-2684 | Received 10 Jan 2022, Accepted 13 Feb 2022, Published online: 23 Feb 2022

References

  • Atalay S, van den Reek J, den Broeder AA, et al. Comparison of tightly controlled dose reduction of biologics with usual care for patients with psoriasis: a randomized clinical trial. JAMA Dermatol. 2020;156(4):393–400.
  • Atalay S, van den Reek J, Otero ME, et al. Health economic consequences of a tightly controlled dose reduction strategy for adalimumab, etanercept and ustekinumab compared with standard psoriasis care: a cost-utility analysis of the CONDOR study. Acta Derm Venereol. 2020;100(19):adv00340.
  • van Muijen ME, van der Schoot LS, van den Reek J, et al. Attitudes and behaviour regarding dose reduction of biologics for psoriasis: a survey among dermatologists worldwide. Arch Dermatol Res. 2021.doi: 10.1007/s00403-021-02273-4.
  • Ducourau E, Mulleman D, Paintaud G, et al. Antibodies toward infliximab are associated with low infliximab concentration at treatment initiation and poor infliximab maintenance in rheumatic diseases. Arthritis Res Ther. 2011;13(3):R105.
  • Bendtzen K, Geborek P, Svenson M, et al. Individualized monitoring of drug bioavailability and immunogenicity in rheumatoid arthritis patients treated with the tumor necrosis factor alpha inhibitor infliximab. Arthritis Rheum. 2006;54(12):3782–3789.
  • Schreiber S, Khaliq-Kareemi M, Lawrance IC, et al. Maintenance therapy with certolizumab pegol for Crohn's disease. N Engl J Med. 2007;357(3):239–250.
  • Menting SP, van Lumig PP, de Vries AC, et al. Extent and consequences of antibody formation against adalimumab in patients with psoriasis: one-year follow-up. JAMA Dermatol. 2014;150(2):130–136.
  • Tsakok T, Wilson N, Dand N, et al. Association of serum ustekinumab levels with clinical response in psoriasis. JAMA Dermatol. 2019;155(11):1235–1243.
  • Detrez I, Brouwers E, Peeters M, et al. Characterization and application of a unique panel of monoclonal antibodies generated against etanercept. JI. 2016;196(6):2879–2884.
  • Strand V, Balsa A, Al-Saleh J, et al. Immunogenicity of biologics in chronic inflammatory diseases: a systematic review. BioDrugs. 2017;31(4):299–316.
  • van Bezooijen JS, van Doorn MBA, Schreurs MWJ, et al. Prolongation of biologic dosing intervals in patients with stable psoriasis: a feasibility study. Ther Drug Monit. 2017;39(4):379–386.
  • van Herwaarden N, Bouman CAM, van der Maas A, et al. Adalimumab and etanercept serum (anti)drug levels are not predictive for successful dose reduction or discontinuation in rheumatoid arthritis. Ann Rheum Dis. 2015;74(12):2260–2261.
  • Moots RJ, Xavier RM, Mok CC, et al. The impact of anti-drug antibodies on drug concentrations and clinical outcomes in rheumatoid arthritis patients treated with adalimumab, etanercept, or infliximab: results from a multinational, real-world clinical practice, non-interventional study. PLOS One. 2017;12(4):e0175207.
  • Chiu HY, Wang TS, Chan CC, et al. Risk factor analysis for the immunogenicity of adalimumab associated with decreased clinical response in Chinese patients with psoriasis. Acta Derm Venereol. 2015;95(6):711–716.
  • Ordas I, Mould DR, Feagan BG, et al. Anti-TNF monoclonal antibodies in inflammatory bowel disease: pharmacokinetics-based dosing paradigms. Clin Pharmacol Ther. 2012;91(4):635–646.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.